Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain

dc.contributor
[López de Rioja V, Perramon-Malavez A, López D, Prats C, Alvarez-Lacalle E] Department of Physics, Universitat Politècnica de Catalunya, Castelldefels, Barcelona, Spain. [Basile L, Medina Maestro S] Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Martínez-Solanas É] Agència de Qualitat I Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Coma E, Fina F] Sistema d'Informació dels Serveis d'Atenció Primària, Institut Català de la Salut (ICS), Barcelona, Spain. [Mendioroz Peña J] Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Universitat de Vic - Universitat Central de Catalunya (UVic-UCC), Vic, Spain
dc.contributor
Departament de Salut
dc.contributor.author
Perramon Malavez, Aida
dc.contributor.author
Martinez-Solanas, Erica
dc.contributor.author
Lopez Codina, Daniel
dc.contributor.author
Coma, Ermengol
dc.contributor.author
Fina, Francesc
dc.contributor.author
Prats, Clara
dc.contributor.author
Lopez de Rioja, Victor
dc.contributor.author
Basile, Luca
dc.contributor.author
Medina Maestro, Sergio
dc.contributor.author
Alvarez Lacalle, Enrique
dc.contributor.author
Mendioroz, Jacobo
dc.date.accessioned
2025-10-27T09:41:07Z
dc.date.available
2025-10-27T09:41:07Z
dc.date.issued
2024-05-22T07:59:55Z
dc.date.issued
2024-05-22T07:59:55Z
dc.date.issued
2024-04-27
dc.identifier
López de Rioja V, Basile L, Perramon-Malavez A, Martínez-Solanas É, López D, Medina Maestro S, et al. Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain. Vaccines. 2024 Apr 27; 12(5):466.
dc.identifier
2076-393X
dc.identifier
https://hdl.handle.net/11351/11485
dc.identifier
10.3390/vaccines12050466
dc.identifier.uri
http://hdl.handle.net/11351/11485
dc.description.abstract
Òmicron; Covid-19; Impacte de la vacuna
dc.description.abstract
Ómicron; Covid-19; Impacto de la vacuna
dc.description.abstract
Omicron; Covid-19; Vaccine Impact
dc.description.abstract
In the current COVID-19 landscape dominated by Omicron subvariants, understanding the timing and efficacy of vaccination against emergent lineages is crucial for planning future vaccination campaigns, yet detailed studies stratified by subvariant, vaccination timing, and age groups are scarce. This retrospective study analyzed COVID-19 cases from December 2021 to January 2023 in Catalonia, Spain, focusing on vulnerable populations affected by variants BA.1, BA.2, BA.5, and BQ.1 and including two national booster campaigns. Our database includes detailed information such as dates of diagnosis, hospitalization and death, last vaccination, and cause of death, among others. We evaluated the impact of vaccination on disease severity by age, variant, and vaccination status, finding that recent vaccination significantly mitigated severity across all Omicron subvariants, although efficacy waned six months post-vaccination, except for BQ.1, which showed more stable levels. Unvaccinated individuals had higher hospitalization and mortality rates. Our results highlight the importance of periodic vaccination to reduce severe outcomes, which are influenced by variant and vaccination timing. Although the seasonality of COVID-19 is uncertain, our analysis suggests the potential benefit of annual vaccination in populations >60 years old, probably in early fall, if COVID-19 eventually exhibits a major peak similar to other respiratory viruses.
dc.description.abstract
This research was supported by the Ayudas Fundación BBVA a proyectos investigación científica 2021 under the project BBVA: Epidemiological modelling of SARS-CoV-2 in a post-pandemic surveillance context: an open platform for mid-term scenarios and short-term predictions; the Agència de Gestió d’Ajuts Universitaris i de Recerca, Catalonia [grant number 2021 SGR 00582]; and PID-2022- 139216NB-I00 funded by Ministerio de Ciencia e Innovación (MCIN/ AEI/10.13039/501100011033) and by ‘ERDF: A way of making Europe’, by the European Union.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Vaccines;12(5)
dc.relation
https://doi.org/10.3390/vaccines12050466
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Scientia
dc.subject
COVID-19 (Malaltia) - Vacunació
dc.subject
Catalunya
dc.subject
ORGANISMS::Viruses::RNA Viruses::Nidovirales::Coronaviridae::Coronavirus
dc.subject
HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Services::Preventive Health Services::Primary Prevention::Immunization::Vaccination
dc.subject
Catalonia
dc.subject
ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::servicios preventivos de salud::prevención primaria::inmunización::vacunación
dc.subject
ORGANISMOS::virus::virus ARN::Nidovirales::Coronaviridae::coronavirus
dc.subject
Cataluña
dc.title
Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)